Preferred Label : Febuxostat;
MeSH definition : A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment
of HYPERURICEMIA in patients with chronic GOUT.;
MeSH hyponym : TEI 6720; 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; uloric; 6720, TEI; TEI-6720; TEI6720;
MeSH CAS label : 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-;
MeSH Related Number : 144060-53-7;
Wikipedia link : https://en.wikipedia.org/wiki/Uloric;
Is substance : O;
UNII : 101V0R1N2E;
Origin ID : D000069465;
UMLS CUI : C0249529;
ATC code(s)
ATC code(s)
Allowable qualifiers
Exact mapping(s) to DCI
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment
of HYPERURICEMIA in patients with chronic GOUT.
https://www.has-sante.fr/jcms/p_3152649/fr/adenuric
2020
true
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
Febuxostat
Febuxostat
administration, oral
febuxostat
gout suppressants
xanthine oxidase
hyperuricemia
chronic disease
---
https://ansm.sante.fr/informations-de-securite/Febuxostat-risque-accru-chez-les-patients-traites-par-febuxostat-et-presentant-des-antecedents-de-maladie-cardiovasculaire-majeure-de-mortalite-cardiovasculaire-et-de-mortalite-toutes-causes-confondues-etude-CARES
2019
false
false
false
France
French
hyperuricemia
cardiovascular diseases
Febuxostat
Febuxostat
pharmacovigilance note
guidelines for drug use
gout suppressants
gout suppressants
febuxostat
gout
death
risk
---
https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-krka
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
Febuxostat
Febuxostat
febuxostat
gout suppressants
gout suppressants
drugs, generic
hyperuricemia
adult
gout
arthritis, gouty
Tophus co-occurrent and due to gout (disorder)
hyperuricemia
antineoplastic agents
hyperuricemia
tumor lysis syndrome
administration, oral
chronic disease
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
---
ULORIC (febuxostat) - Increased Risk of Cardiovascular Fatal Outcomes
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/71511a-fra.php
2019
false
false
false
Canada
French
English
Febuxostat
risk
gout suppressants
febuxostat
pharmacovigilance note
cardiovascular diseases
cardiovascular diseases
cause of death
gout
---
https://www.has-sante.fr/portail/jcms/c_2885804/fr/febuxostat-teva-sante
2018
false
false
false
France
drugs, generic
evaluation of the transparency committee
Febuxostat
febuxostat
---
https://www.ema.europa.eu/medicines/human/EPAR/Febuxostat-Mylan
2017
false
United Kingdom
French
English
syndication feed
Febuxostat
Febuxostat
drugs, generic
Product containing precisely febuxostat 80 milligram/1 each conventional release oral
tablet (clinical drug)
drug approval
drug labeling
treatment outcome
gout suppressants
gout suppressants
hyperuricemia
xanthine oxidase
tablets
administration, oral
gout
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
febuxostat
drug evaluation
package leaflet
summary of product characteristics
---
Summary Safety Review - ULORIC (febuxostat) - Assessing the Potential Risk of Heart
Failure
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/uloric2-fra.php
2016
false
false
false
Canada
French
English
pharmacovigilance note
risk assessment
uloric
uloric
gout suppressants
gout suppressants
febuxostat
risk factors
gout
heart failure
Febuxostat
Febuxostat
---
Summary Safety Review - ULORIC (febuxostat) - Assessing a Possible Risk of Drug Reaction/Rash
with Eosinophilia and Systemic Symptoms (DRESS)
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/uloric3-fra.php
2016
false
false
false
Canada
French
English
drug evaluation
risk assessment
canada
Febuxostat
febuxostat
gout suppressants
drug hypersensitivity syndrome
gout
administration, oral
---
http://www.has-sante.fr/portail/jcms/c_2038866/fr/adenuric
2015
true
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
Febuxostat
Febuxostat
administration, oral
febuxostat
gout suppressants
xanthine oxidase
hyperuricemia
chronic disease
---
Summary Safety Review - ULORIC (febuxostat) - Agranulocytosis (severe reduction in
the number of white blood cells)
https://www.hc-sc.gc.ca/dhp-mps/medeff/reviews-examens/uloric-fra.php
2015
false
false
false
Canada
French
English
administration, oral
febuxostat
gout suppressants
agranulocytosis
drug information
neutropenia
Febuxostat
---
Febuxostat and international reports of agranulocytosis and drug rash with eosinophilia
and systemic symptoms (DRESS)
https://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/hpiw-ivps_2015-05-fra.php#s2a
2015
false
false
false
Canada
French
English
febuxostat
pharmacovigilance note
drug hypersensitivity syndrome
agranulocytosis
gout suppressants
hyperuricemia
xanthine oxidase
gout
Febuxostat
---
http://www.cochrane.org/fr/CD008653
2012
false
United Kingdom
France
French
Febuxostat
febuxostat
gout
chronic disease
treatment outcome
gout suppressants
meta-analysis
french abstract
---
http://www.has-sante.fr/portail/jcms/c_1244186/adenuric
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-05/adenuric_11042012_avis_ct12188.pdf
2012
false
France
French
evaluation of the transparency committee
guidelines for drug use
Febuxostat
Febuxostat
administration, oral
febuxostat
gout suppressants
gout suppressants
drug hypersensitivity
renal insufficiency
medical history taking
xanthine oxidase
hyperuricemia
chronic disease
risk factors
---
https://www.ema.europa.eu/medicines/human/EPAR/Adenuric
2012
false
United Kingdom
French
English
syndication feed
Febuxostat
Febuxostat
drug approval
drug labeling
treatment outcome
gout suppressants
gout suppressants
hyperuricemia
xanthine oxidase
tablets
administration, oral
gout
adult
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
febuxostat
drug evaluation
package leaflet
summary of product characteristics
---
Summary Basis of Decision (SBD) for ULORIC (Febuxostat)
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00158
2010
false
Canada
English
French
Febuxostat
xanthine oxidase
gout suppressants
drug approval
hyperuricemia
treatment outcome
administration, oral
canada
febuxostat
drug information
---
http://www.has-sante.fr/portail/jcms/c_858615/synthese-d-avis-adenuric-ct-6315
http://www.has-sante.fr/portail/jcms/c_827795/adenuric-ct-6315
http://www.has-sante.fr/portail/jcms/c_858616/adenuric-febuxostat-inhibiteur-de-la-xanthine-oxydase
2009
false
France
French
Febuxostat
Febuxostat
chronic disease
treatment outcome
gout suppressants
hyperuricemia
gout suppressants
xanthine oxidase
administration, oral
febuxostat
insurance, health, reimbursement
evaluation of the transparency committee
guidelines for drug use
---
https://www.cadth.ca/sites/default/files/pdf/438_febuxostat_cetap_f.pdf
https://www.cadth.ca/sites/default/files/pdf/438_Febuxostat_cetap_e.pdf
2006
false
Canada
French
English
Febuxostat
Febuxostat
hyperuricemia
gout
xanthine oxidase
gout suppressants
Evidence-Based medicine
canada
clinical trials, phase iii as topic
gout suppressants
febuxostat
journal article
drug evaluation
---